Floatz logo

Muromonab-Cd3

Chronic Myeloid Leukemia

St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Thiotepa
Leland Metheny
Phase 3BB
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB
Bendamustine
St. Petersburg State Pavlov Medical University
Phase 2B
Idarubicine
M.D. Anderson Cancer Center
Phase 2B
Azacitidine
The First Affiliated Hospital of Soochow University
Phase 2B

View all 44 →

Same molecule, other indications

Muromonab-Cd3 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
Myelodysplastic Syndrome (MDS)Dormant
BB
Indicative ·
69 / 100
View asset →
paroxysmal nocturnal hemoglobinuriaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →